Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesGlobeNewsWire • 04/08/24
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research MeetingGlobeNewsWire • 03/19/24
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian CancerGlobeNewsWire • 03/14/24
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business HighlightsGlobeNewsWire • 03/05/24
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor ConferencesGlobeNewsWire • 02/09/24
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/24
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 11/08/23
Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)Zacks Investment Research • 10/16/23
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate PresentationGlobeNewsWire • 09/25/23
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900GlobeNewsWire • 09/06/23
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of CholangiocarcinomaGlobeNewsWire • 08/17/23
Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 08/09/23
Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep goingZacks Investment Research • 06/05/23
Wall Street Analysts Think Nuvectis Pharma, Inc. (NVCT) Could Surge 29.35%: Read This Before Placing a BetZacks Investment Research • 05/15/23
Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business HighlightsGlobeNewsWire • 05/10/23
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceGlobeNewsWire • 04/27/23
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian CarcinomaGlobeNewsWire • 04/10/23